BTIG Reiterates Buy on Abivax, Maintains $175 Price Target
BTIG analyst Julian Harrison reiterates Abivax (NASDAQ:ABVX) with a Buy and maintains $175 price target.
Stocks · News reference
Stocks up, Dow Jones +100 points. AEVEX Corp shares rose 11.8% on $50m Air Force contract. Other big gainers: ABVX +34.2%, ESBA +20.9%, AVAV +20.4%, AIRJ +17.4%, FCEL +14%, UMAC +11.1%, HSAI +10.7%, PROK +9.3%, WOLF +9.1%, APD +8.6%
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
BTIG analyst Julian Harrison reiterates Abivax (NASDAQ:ABVX) with a Buy and maintains $175 price target.
Abivax missed EPS estimates but beat sales in H1; shares dipped. Wedbush and Truist cut price targets to $118 and $151.
Truist Securities analyst Gregory Renza maintains Abivax (NASDAQ:ABVX) with a Buy and lowers the price target from $155 to $151.
Wedbush analyst David Nierengarten maintains Abivax (NASDAQ:ABVX) with a Neutral and lowers the price target from $140 to $118.
Filed: 2026-09-14 AccNo: 0001193125-26-389855 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
The transaction also includes up to $40 million of additional consideration payable in AIRJ common stock based on BitSink achieving revenue milestones over the three calendar years following closing, aligning a majority